A PHASE I / II TRIAL OF THE HDAC INHIBITOR BELINOSTAT IN COMBINATION WITH ERLOTINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER.

被引：0
|
作者：
Andersen, Jon L. [1 ]
Holm, Bente [1 ]
Rasmussen, Trine S. [1 ]
Mellemgaard, Anders [1 ]
机构：
[1] Copenhagen Univ Hosp Herlev, Copenhagen, Denmark
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
NSCLC advanced; Phase I; Belinostat/Erlotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.11-030
引用
收藏
页码：S1201 / S1202
页数：2
相关论文
共 50 条
  • [1] A phase I/II trial of MM-121 in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).
    Sequist, L. V.
    Harb, W. A.
    Modiano, M.
    Jackman, D. M.
    Wong, K.
    Engelman, J. A.
    Nering, R.
    Onsum, M.
    Moyo, V. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer.
    Komaki, R.
    Blumenschein, G. R.
    Wistuba, I. I.
    Lee, J. J.
    Allen, P.
    Wei, X.
    Welsh, J.
    O'Reilly, M.
    Herbst, R. S.
    Tang, X.
    Meyn, R.
    Liu, D.
    Hong, W. K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] PHASE II TRIAL OF ERLOTINIB IN PREVIOUSLY TREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Okano, Yoshio
    Shinohara, Tsutomu
    Machida, Hisanori
    Hatakeyama, Nobuo
    Takeuchi, Eiji
    Doi, Hiroyuki
    Kubota, Tetsuya
    Yokoyama, Akihito
    Ogushi, Fumitaka
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1175 - S1176
  • [4] Erlotinib in combination with bevacizumab for patients with recurrent non-small-cell lung cancer: a phase I/II trial
    Herbst, Roy S.
    Johnson, David
    Blumenschein, George
    Henderson, Ted
    Liu, Diane
    Truong, Mylene
    Ramies, David
    Mass, Robert
    Garcia, Ben
    Sandler, Alan B.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 170 - 170
  • [5] Preoperative erlotinib in clinical stage I and II non-small cell lung cancer.
    Port, J. L.
    Yankelevitz, D.
    Lee, P. C.
    Spinelli, C.
    Altorki, N. K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] A phase II study of vorolanib in combination with toripalimab in patients with non-small cell lung cancer.
    Zhao, Jun
    Li, Jianjie
    Chen, Hanxiao
    Yang, Xue
    Zhong, Jia
    Zhuo, Minglei
    Jia, Bo
    An, Tongtong
    Wu, Meina
    Wang, Ziping
    Ding, Lieming
    Mao, Li
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Phase I trial of vorinostat in combination with erlotinib in advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations after erlotinib progression
    Reguart, N.
    Cardona, A. F.
    Isla, D.
    Cardenal, F.
    Palmero, R.
    Carrasco-Chaumel, E.
    Rolfo, C.
    Massuti, B.
    Moran, T.
    Rosell, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
    Sequist, Lecia, V
    Gray, Jhanelle Elaine
    Harb, Wael A.
    Lopez-Chavez, Ariel
    Doebele, Robert C.
    Modiano, Manuel R.
    Jackman, David Michael
    Baggstrom, Maria Quintos
    Atmaca, Akin
    Felip, Enriqueta
    Provencio, Mariano
    Cobo, Manuel
    Adiwijaya, Bambang
    Kuesters, Geoffrey
    Kamoun, Walid S.
    Andreas, Karen
    Pipas, J. Marc
    Santillana, Sergio
    Cho, Byoung Chul
    Park, Keunchil
    Shepherd, Frances A.
    [J]. ONCOLOGIST, 2019, 24 (08): : 1095 - 1102
  • [9] Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer.
    Sandler, AB
    Blumenschein, GR
    Henderson, T
    Lee, J
    Truong, M
    Kim, E
    Mass, B
    Garcia, B
    Johnson, DH
    Herbst, RS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 127S - 127S
  • [10] A Phase I/II Study Combining Erlotinib andDasatinib for Non-Small Cell Lung Cancer
    Gold, Kathryn A.
    Lee, J. Jack
    Harun, Nusrat
    Tang, Ximing
    Price, Justina
    Kawedia, Jitesh D.
    Tran, Hai T.
    Erasmus, Jeremy J.
    Blumenschein, George R.
    William, Awilliam N.
    Wistuba, Ignacio I.
    Johnson, Faye M.
    [J]. ONCOLOGIST, 2014, 19 (10): : 1040 - 1041
12345